Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William C Gerth

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Current Hypertension Reports|November 7, 2002
Compliance and persistence with newer antihypertensive agentsWilliam C Gerth
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|May 30, 2014
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in CanadaWilliam C Gerth, Stephen D Betschel, Arthur S Zbrozek
Journal of Occupational and Environmental Medicine|January 16, 2004
Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and modelWilliam C Gerth, Syam Sarma, X Henry Hu, et al.
The Canadian Journal of Cardiology|July 11, 2002
Antihypertensive persistence and drug classMichael A Marentette, William C Gerth, David K Billings, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 21, 2004
Burden of hospitalization of patients with Candida and Aspergillus infections in AustraliaMonica Slavin, John Fastenau, Isaya Sukarom, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 16, 2004
Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?Hans-Georg Eichler, Sheldon X Kong, William C Gerth, et al.
The Canadian Journal of Cardiology|May 21, 2004
Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspectiveEllen D Burgess, George W Carides, William C Gerth, et al.
The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique|November 8, 2002
Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a phase III clinical trialJean Lambert, George W Carides, Jacques P Meloche, et al.
Pharmacoepidemiology and Drug Safety|January 18, 2005
Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactionsD Tony Yu, Josh F Peterson, Diane L Seger, et al.
Clinical Therapeutics|August 25, 2005
Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysisJohn R Wingard, Craig A Wood, Elizabeth Sullivan, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Current Hypertension Reports|November 7, 2002
Compliance and persistence with newer antihypertensive agentsWilliam C Gerth
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|May 30, 2014
Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in CanadaWilliam C Gerth, Stephen D Betschel, Arthur S Zbrozek
Journal of Occupational and Environmental Medicine|January 16, 2004
Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and modelWilliam C Gerth, Syam Sarma, X Henry Hu, et al.
The Canadian Journal of Cardiology|July 11, 2002
Antihypertensive persistence and drug classMichael A Marentette, William C Gerth, David K Billings, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 21, 2004
Burden of hospitalization of patients with Candida and Aspergillus infections in AustraliaMonica Slavin, John Fastenau, Isaya Sukarom, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 16, 2004
Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?Hans-Georg Eichler, Sheldon X Kong, William C Gerth, et al.
The Canadian Journal of Cardiology|May 21, 2004
Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspectiveEllen D Burgess, George W Carides, William C Gerth, et al.
The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique|November 8, 2002
Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a phase III clinical trialJean Lambert, George W Carides, Jacques P Meloche, et al.
Pharmacoepidemiology and Drug Safety|January 18, 2005
Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactionsD Tony Yu, Josh F Peterson, Diane L Seger, et al.
Clinical Therapeutics|August 25, 2005
Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysisJohn R Wingard, Craig A Wood, Elizabeth Sullivan, et al.
Pageof 2